Celsentri

RSS

maraviroc

Authorised
This medicine is authorised for use in the European Union.

Overview

This is a summary of the European public assessment report (EPAR) for Celsentri. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Celsentri.

For practical information about using Celsentri, patients should read the package leaflet or contact their doctor or pharmacist.

This EPAR was last updated on 28/09/2020

Authorisation details

Product details
Name
Celsentri
Agency product number
EMEA/H/C/000811
Active substance
maraviroc
International non-proprietary name (INN) or common name
maraviroc
Therapeutic area (MeSH)
HIV Infections
Anatomical therapeutic chemical (ATC) code
J05AX09
Publication details
Marketing-authorisation holder
ViiV Healthcare B.V.
Revision
26
Date of issue of marketing authorisation valid throughout the European Union
18/09/2007
Contact address

Van Asch van Wijckstraat 55 H
3811 LP Amersfoort
The Netherlands

Product information

07/09/2020 Celsentri - EMEA/H/C/000811 - IB/0064

Contents

Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.

Pharmacotherapeutic group

Antivirals for systemic use

Therapeutic indication

Celsentri, in combination with other antiretroviral medicinal products, is indicated for treatment experienced adults, adolescents and children of 2 years of age and older and weighing at least 10 kg infected with only CCR5-tropic HIV-1 detectable

Assessment history

How useful was this page?

Add your rating